Indigo is a EC Horizon 2020 project in partnership with India’s Department of Biotechnology
Dr. Sanjay Singh (Male): Dr. Sanjay Singh is the Chief Executive Officer of Gennova Biopharmaceuticals Ltd, Pune, India, a biotechnology company dedicated to the development and commercialization of safe, efficacious and affordable bio-therapeutics.
After obtaining a PhD in Biochemistry from Central Drug Research Institute (CDRI), Lucknow, India, Dr. Singh worked on malaria vaccine development first at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India and then at the National Institute of Health (NIH), USA where he eventually headed the Antigen Research Section at the Malaria Vaccine Development Branch of the National Institutes of Allergy and Infectious Diseases (NIAID), NIH, USA. During his tenure at the NIH, he was successful in taking four recombinant vaccine candidates from gene to human clinical trials.
In 2006, he joined as the CEO of Gennova Biopharmaceuticals Ltd., which was then a startup biotechnology company. At Gennova, Dr. Singh’s leadership has facilitated the launch of various therapeutic life-saving biologics in the cardiovascular, renal care and oncology market. His focus on innovations in bio-manufacturing technologies has made the drugs affordable to the masses and today, under his guidance Gennova is the market leader in four of its products. Two of the biosimilars (Tenecteplase and Pegaspargase) launched were the first biosimilar to be launched globally. Realizing the potential of the use of Tenecteplase for stroke Dr. Singh pioneered its approval for acute ischemic stroke – the first time globally.
Under him Gennova has diversified into vaccine research specifically in the area of infectious diseases, in particular Malaria, HPV, Leishmaniasis and Tuberculosis in partnership with various national and global organizations. His commitment to this filed is accentuated by the fact that today Gennova is the only supplier of cGMP grade vaccine adjuvant GLA-SE, which has proven successful in the recently concluded Ph1 CT for a malaria vaccine candidate.
Dr Singh is a member of the Central Drugs Standard Control Organization (CDSCO), Drug Controller General of India (DCGI), Ministry of Health, Govt. of India for development of the Indian Guidelines on Similar Biologics (Regulatory Requirements for Marketing Authorization). He also serves as a member of the Governing body of the Institute of Life Sciences (ILS) – Bhubaneswar, an autonomous institute of Department of Biotechnology (DBT), Govt. of India. Member of the advisory board of ILS –Ahmedabad. Additionally, he is part of the working group for Gene Therapy constituted jointly by the Department of Health Research (DHR) and Department of Biotechnology (DBT), Govt. of India.